Publications:  Dr Julie Foster

Demircioglu F, Wang J, Candido J, Costa ASH, Casado P, de Luxan Delgado B, Reynolds LE, Gomez-Escudero J et al.(2020). Cancer associated fibroblast FAK regulates malignant cell metabolism. Nature Communications vol. 11, (1) 1290-1290.

Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J, Halldén G(2019). Systemic delivery and SPECT/CT in vivo imaging of ¹²⁵I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports vol. 9, (1)

Crnogorac-Jurcevic T, Radon T, Shah S, Weeks M, Foster J, Sosabowski J, Dumartin L(2019). AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. Oncotarget

Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Decristoforo C, Virgolini I et al.(2019). DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. J Nucl Med vol. 60, (7) 1010-1016.

Zhai C, He S, Ye Y, Rangger C, Kaeopookum P, Summer D, Haas H, Kremser L et al.(2019). Rational design, synthesis and preliminary evaluation of novel fusarinine C-based chelators for radiolabeling with Zirconium-89. Biomolecules vol. 9, (3)

Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E(2019). Erratum: Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics vol. 9, (16) 4595-4596.

Deshayes E, Ladjohounlou R, Le Fur P, Pichard A, Lozza C, Boudousq V, Sevestre S, Jarlier M et al.(2018). Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. J Nucl Med vol. 59, (8) 1234-1242.

Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E(2018). Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. Theranostics vol. 8, (11) 2896-2908.

Emami-Shahri N, Foster J, Kashani R, Gazinska P, Cook C, Sosabowski J, Maher J, Papa S(2018). Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. Nature Communications vol. 9, (1) 1081-1081.

Rudran B, Desai A, Luzarraga M, Hodivala-Dilke K, Foster J, Sosabowski J, Marshall J (2017). Development of non-invasive imaging of integrin alpha-v-beta-6 (alpha v beta 6)-positive lung cancers in advance of testing alpha v beta 6-targeted therapies. Lung Cancer. Conference: British Thoracic Oncology Group Conference 2017 (Dublin, Ireland) from: 25/01/2017 to: 27/01/2017, vol. 103, S4-S4.

Maher J, Wilkie S, Davies DM, Arif S, Picco G, Julien S, Foster J, Burchell J et al.(2016). Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells. Immunity vol. 45, (5) 945-946.

Emami-Shahri N, Foster J, Sosabowski J, Maher J, Papa S (2016). Dynamic SPECT imaging of PSMA-specific CAR T cells in mice bearing prostate cancer. CANCER RESEARCH. vol. 76,

Tremoleda JL, Thau-Zuchman O, Davies M, Foster J, Khan I, Vadivelu KC, Yip PK, Sosabowski J et al.(2016). In vivo PET imaging of the neuroinflammatory response in rat spinal cord injury using the TSPO tracer [18F]GE-180 and effect of docosahexaenoic acid. European Journal of Nuclear Medicine and Molecular Imaging

Castillo SD, Tzouanacou E, Zaw-Thin M, Berenjeno IM, Parker VER, Chivite I, Milà-Guasch M, Pearce W et al.(2016). Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Science Translational Medicine vol. 8, (332)

Tremoleda JL, Thau-Zuchman O, Davies M, Foster J, Khan I, Trigg W, Sosabowski J, Mather SJ et al. (2015). IN VIVO IMAGING OF NEUROINFLAMMATION IN NEUROTRAUMA PRECLINICAL MODELS: POTENTIAL FOR CLINICAL TRANSLATION. SHOCK. vol. 44, 24-25.

Pujatti PB, Foster JM, Finucane C, Hudson CD, Burnet JC, Pasqualoto KFM, Mengatti J, Mather SJ et al.(2015). Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models. Applied Radiation and Isotopes vol. 96, 91-101.

Parente-Pereira AC, Shmeeda H, Whilding LM, Zambirinis CP, Foster J, van der Stegen SJC, Beatson R, Zabinski T et al.(2014). Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid. J Immunol vol. 193, (11) 5557-5566.

Mullen L, Adams G, Foster J, Vessillier S, Köster M, Hauser H, Layward L, Gould D et al.(2014). A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints. Ann Rheum Dis vol. 73, (9) 1728-1736.

Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Marzec J, Vasiljevi¿ N, Chaplin T et al.(2014). Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol vol. 232, (5) 566-577.

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M et al.(2014). Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res vol. 74, (3) 896-907.

Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Marzec J, Vasiljevíc N, Chaplin T et al.(2014). Erratum:Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014); 232: 566-577)). Journal of Pathology vol. 234, (1)

Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Marzec J, Vasiljevic N, Chaplin T, Foster JM et al.(2014). Identification of ZDHHC14 as a novel human tumour suppressor: gene. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE vol. 34, S90-S90.

Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C et al.(2014). Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. Expert Opin Drug Deliv vol. 11, (1) 5-16.

Roosenburg S, Laverman P, Joosten L, Cooper MS, Kolenc-Peitl PK, Foster JM, Hudson C, Leyton J et al.(2014). PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with ⁶⁴Cu, ⁶⁸Ga, and ¹¹¹In. Molecular Pharmaceutics vol. 11, (11) 3930-3937.

van der Stegen SJC, Davies DM, Wilkie S, Foster J, Sosabowski JK, Burnet J, Whilding LM, Petrovic RM et al.(2013). Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?. J Immunol vol. 191, (9) 4589-4598.

Kogelberg H, Miranda E, Burnet J, Ellison D, Tolner B, Foster J, Picón C, Thomas GJ et al.(2013). Generation and characterization of a diabody targeting the αvβ6 integrin. PLoS One vol. 8, (9)

Coulstock E, Sosabowski J, Ove¿ka M, Prince R, Goodall L, Mudd C, Sepp A, Davies M et al.(2013). Liver-targeting of interferon-alpha with tissue-specific domain antibodies. PLoS One vol. 8, (2)

Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D et al.(2012). Contrasting effects of sunitinib within in vivo models of metastasis. ANGIOGENESIS vol. 15, (4) 623-641.

Joosten L, Sosabowski JK, Cooper MS, Foster J, Burnet J, Oyen WJG, Boerman OC, Blower PJ et al. (2012). PET and SPECT Imaging of a CCK2 Receptor-Binding Peptide Comparing Various Chelators and Radionuclides. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. vol. 39, S241-S241.

Al-Jamal KT, Nunes A, Methven L, Ali-Boucetta H, Li S, Toma FM, Herrero MA, Al-Jamal WT et al.(2012). Degree of chemical functionalization of carbon nanotubes determines tissue distribution and excretion profile. Angew Chem Int Ed Engl vol. 51, (26) 6389-6393.

Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Chaplin T, Xue L, Xu M et al.(2012). Identification of ZDHHC14 as a novel tumor suppressor gene commonly downregulated in human cancers. CANCER RESEARCH vol. 72,

Davies DM, Foster J, van der Stegen SJC, Parente-Pereira AC, Chiapero-Stanke L, Delinassios GJ, Burbridge SE, Kao V et al.(2012). Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells. MOLECULAR MEDICINE vol. 18, (4) 565-576.

Davies DM, Pereira ACP, van der Stegen SJCT, Brewig N, Foster J, Mather SJ, Wilkie S, Ghaem-Maghami S et al.(2011). Flexible targeting of diverse ErbB dimers that drive tumorigenesis using genetically targeted T-cells. HUMAN GENE THERAPY vol. 22, (10) A118-A118.

van der Stegen SJC, Foster JM, Davies DM, Pereira ACP, Mather SJ, Wilkie S, Maher J(2011). In vivo toxicity assessment of genetically-engineered T-cells targeting the ErbB receptor family. HUMAN GENE THERAPY vol. 22, (10) A123-A124.

Finucane C, Masciotti J, Foster J, McInerney J, Shulman S(2011). X-ray CT with Gold Nanoparticles. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 38, S176-S176.

Parente-Pereira AC, Burnet J, Ellison D, Foster J, Davies DM, van der Stegen S, Burbridge S, Chiapero-Stanke L et al.(2011). Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol vol. 31, (4) 710-718.

Lopez de Heredia L, Gengatharan A, Foster J, Mather S, Magoulas C(2011). Bioluminescence imaging of the brain response to acute inflammation in living C/EBP reporter mice. Neurosci Lett vol. 497, (2) 134-138.

Parente-Pereira AC, Burnet J, Ellison D, Foster J, Davies DM, van der Stegen S, Burbridge S, Chiapero-Stanke L et al.(2011). Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice. Journal of Clinical Immunology1-9.

Finucane CM, Murray I, Sosabowski JK, Foster JM, Mather SJ(2011). Quantitative Accuracy of Low-Count SPECT Imaging in Phantom and In Vivo Mouse Studies. Int J Mol Imaging vol. 2011,

Sosabowski J, Finucane C, Foster J, Ellison D, Burnet J, Mather S (2010). Comparison Of 111-In Labelled CCK2-Receptor Targeting Peptides Using Nanospect/CT Imaging, A Collaborative Project Under COST BM0607. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. vol. 37, S268-S268.

Torres Martin de Rosales R, Finucane C, Foster J, Mather SJ, Blower PJ(2010). 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. Bioconjug Chem vol. 21, (5) 811-815.

Wilkie S, Burbridge S, Davies DM, Chiapero-Stanke L, Foster J, Mather SJ, Maher J (2010). Genetic engineering of pharmacologically regulated T cells, specific for breast cancer target antigens. BREAST CANCER RESEARCH. vol. 12, S16-S16.

Sosabowski JK, Matzow T, Foster JM, Finucane C, Ellison D, Watson SA, Mather SJ(2009). Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med vol. 50, (12) 2082-2089.

Sosabowski J, Matzow T, Foster J, Mather S(2009). TARGETING OF CCK2 RECEPTOR EXPRESSING TUMOURS USING AN 111IN-LABELLED MINIGASTRIN DIMER. J LABELLED COMPD RAD vol. 52, S327-S327.

Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ et al.(2008). Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor. J IMMUNOL vol. 180, (7) 4901-4909.

Wilkie S, Picco G, Foster J, Davies D, Julien S, Cooper L, Arif S, Mather S et al. (2008). Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes. BREAST CANCER RESEARCH. vol. 10, S4-S5.